Bionaut Labs’ fantastic voyage continues, with $43.2 million in new venture capital funding to help build up its tiny robots into machines capable of swimming through the human body and delivering drugs where some therapies and surgeons can’t reach.
Bionaut Labs, and Candel Therapeutics, have announced a nstrategic collaboration to investigate the use of Bionaut’s nremote-controlled microscale robots for prevision delivery of Candel’s noncolytic viral immunotherapy agents to specific brain tumours.